Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies

Condition:   Primary Immunodeficiency Diseases (PID) Intervention:   Drug: Cutaquig Sponsor:   Federal Research Institute of Pediatric Hematology, Oncology and Immunology Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials